Related Experiment Video
Updated: Aug 9, 2025
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
Pacritinib abrogates the lupus phenotype in ABIN1[D485N] mice
Tsvetana Petrova1, Clara Figueras-Vadillo1, Sambit K Nanda1
1MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK.
Objective:
The aim of the study was to investigate whether the IRAK1/JAK2/Flt3 inhibitor pacritinib prevents disease development in the lupus-prone ABIN1[D485N] knock-in mouse.
Methods:
ABIN1[D485N] knock-in mice aged 8 weeks were fed for 10 weeks on a diet containing pacritinib. Body weight was monitored, and serum collected at the end to measure pacritinib, autoantibody and immunoglobulin levels. Splenic immune cell populations were analysed, and the kidney, liver and lungs examined for pathology.
Results:
Pacritinib prevented multiple facets of the lupus phenotype in ABIN1[D485N] knock-in mice, including splenomegaly, expansion of splenic germinal centre B cells, follicular T helper cells, and neutrophils, elevated serum levels of double-stranded DNA antibodies and immunoglobulins, glomerular IgA and lung inflammation.
Conclusions:
Pacritinib may be useful for the treatment of multiorgan inflammation in patients with lupus.
